Fulcrum Therapeutics (FULC) Change in Accured Expenses (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Change in Accured Expenses data on record, last reported at -$3.8 million in Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 12.75% to -$3.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $599000.0, a 232.82% increase, with the full-year FY2025 number at $1.0 million, up 199.32% from a year prior.
  • Change in Accured Expenses reached -$3.8 million in Q1 2026 per FULC's latest filing, down from $2.3 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for FULC hit a ceiling of $5.8 million in Q2 2022 and a floor of -$4.5 million in Q3 2022.
  • A 5-year average of -$237823.5 and a median of $587000.0 in 2025 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: crashed 289.74% in 2022, then surged 525.16% in 2024.
  • Tracing FULC's Change in Accured Expenses over 5 years: stood at $1.6 million in 2022, then plummeted by 41.81% to $909000.0 in 2023, then tumbled by 170.41% to -$640000.0 in 2024, then surged by 457.97% to $2.3 million in 2025, then tumbled by 264.38% to -$3.8 million in 2026.
  • Business Quant data shows Change in Accured Expenses for FULC at -$3.8 million in Q1 2026, $2.3 million in Q4 2025, and $1.5 million in Q3 2025.